Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4383eff7d424f33a5252d6973036a564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
filingDate |
2013-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2016-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cd993e2949f90c692c25f8d95e0085b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_accb69da438a66668605d89c10e8fee6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eda588ffadc97782e30c2ebc41390951 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e43184b90aa3e2cd6a69c87633dada80 |
publicationDate |
2016-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2013203204-B2 |
titleOfInvention |
Complexes of il-15 and il-15r.alpha and uses thereof |
abstract |
The present invention relates to agents that modulate interleukin-15 ("I0-15") signal transduction or function ("Therapeutic Agents") and the use of those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and moduate IL-iS induced signal transduction. The Therapeutic Agents may be formulated with polymerssuch as poly-p-1 * 4N-acetylglucosamine, for administration to a human subject to modulate IL-15-mediated immune function. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3639845-A4 |
priorityDate |
2007-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |